 |
|
|
|||||||||
|
PatentsDiaKine holds an exclusive, world-wide license to develop and market products based on the discoveries associated with Lisofylline and the next generation of orally bioavailable immune modulators with a similar spectrum of action for the treatment of both type 1 and type 2 diabetes and related complications. The Company holds more than 50 patents and patent applications and the Investigational New Drug Application (IND) for LSF.
|
||||||||||
|
|
|
|
|
||||||||
|
©2006 DiaKine Therapeutics. All rights reserved.
|
|||||||||||
